Company-led submission pilot for early evaluation of non-cancer drugs

ACE is conducting a pilot of the company-led submission process for selected non-cancer drugs expecting regulatory approval from Q2 2024 onwards. Non-cancer drugs that are used across all therapeutic areas are eligible. Companies are encouraged to provide information about their drug pipeline during the annual horizon scanning exercise to inform topic selection.

More information about ACE's company-led submission process can be found here.